Peptides isolated from venoms of cone snails, snakes, scorpions, tarantulas, and sea anemones target specific peripheral pain receptors and show strong analgesic effects in animal models, offering potential alternatives to opioids.
6 venomous animal groups yield analgesic peptidesCone snails, snakes, sea anemones, tarantulas, scorpions, and spiders all produce peptides that target specific peripheral pain receptors — one (ziconotide) is already FDA-approved
What the researchers found
The review identifies multiple families of venom-derived analgesic peptides from cone snails, snakes, sea anemones, tarantulas, scorpions, and spiders. These peptides target key peripheral pain receptors including TRPV1, TRPV2, voltage-gated sodium, calcium, and potassium channels, and acid-sensing ion channels (ASICs). Animal studies demonstrate robust analgesic effects across various pain types. The specificity of these venom peptides for individual ion channel subtypes gives them potential advantages over existing analgesics.
Why it matters
The opioid crisis has created urgent demand for non-opioid analgesics that can effectively treat pain without addiction risk. Venom-derived peptides represent one of nature's most refined approaches to modulating nervous system signaling. One venom peptide (ziconotide, from cone snails) is already FDA-approved for severe chronic pain, proving the concept works. This review maps the broader landscape of venom peptides that could become the next generation of pain medications.
How the study worked
Narrative review of the literature on venom-derived peptides that target peripheral pain pathways. The review covers the pathophysiology of peripheral pain receptors, catalogs analgesic peptides from various venomous species, and summarizes their mechanisms of action and preclinical efficacy data.
What this study cannot tell us
This is a narrative review without systematic methodology. Most evidence for venom-derived analgesic peptides comes from animal models, and translation to human pain conditions is uncertain. Venom peptides often require injection (some intrathecally), limiting practical clinical use. Peptide stability, manufacturing costs, and potential immunogenicity are ongoing challenges. The review focuses on peripheral pain, and efficacy against central pain conditions is less explored.
How to read the evidence
This is a narrative review summarizing preclinical evidence from animal models. While the body of evidence for venom-derived analgesic peptides is growing, most candidates remain in early research stages. Only ziconotide has achieved clinical approval.
When this study was published
Published in 2025, this review captures the current state of venom peptide-based analgesic research, a field gaining momentum as the search for non-opioid pain treatments intensifies.
The bigger picture
Nature has spent millions of years evolving venom peptides that precisely manipulate ion channels — the exact molecular targets that pain researchers are trying to drug. The success of ziconotide (from cone snail venom) validates this approach, and the thousands of venom peptides yet to be fully characterized represent a vast untapped pharmacological resource. As peptide drug delivery and manufacturing technologies improve, more venom-derived analgesics could reach clinical use, offering targeted pain relief that avoids the addiction and tolerance problems of opioids.
Questions still open
- Which of the many venom-derived analgesic peptides are closest to clinical development for human pain management?
- Can venom peptides be modified for oral or topical delivery to avoid the need for injection?
- Could combinations of venom peptides targeting different pain receptors provide synergistic analgesia?
Common questions
Are there already pain medications made from venom?
How could venom peptides be better than opioids for pain?
Read the original research
From Discovery to the Future Medical Applications of Venom-derived Analgesic Peptides for the Treatment of Peripheral Pains.
Current pharmaceutical design
Citation
Bagheri-Ziari, Sedigheh; Bagheri, Kamran Pooshang. (2025). From Discovery to the Future Medical Applications of Venom-derived Analgesic Peptides for the Treatment of Peripheral Pains.. Current pharmaceutical design. https://doi.org/10.2174/0113816128368659250805054737